Heterogeneity across outcomes in clinical trials on sodium-glucose cotransporter 2 inhibitors in chronic heart failure: a cross-sectional study

IF 7.3 2区医学 Q1 HEALTH CARE SCIENCES & SERVICES

Journal of Clinical Epidemiology Pub Date : 2025-01-23 DOI:10.1016/j.jclinepi.2025.111685

Fran Šaler , Marin Viđak , Ružica Tokalić , Livia Puljak

{"title":"Heterogeneity across outcomes in clinical trials on sodium-glucose cotransporter 2 inhibitors in chronic heart failure: a cross-sectional study","authors":"Fran Šaler , Marin Viđak , Ružica Tokalić , Livia Puljak","doi":"10.1016/j.jclinepi.2025.111685","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><div>This study aimed to analyze the outcomes, outcome domains, and prevalence of the use of clinical outcome endpoints (COE) in clinical trials on sodium-glucose cotransporter 2 (SGLT2) inhibitors for chronic heart failure (CHF) registered on ClinicalTrials.gov and compare them to COE for cardiovascular trials.</div></div><div><h3>Study Design and Setting</h3><div>We conducted a cross-sectional methodological study. Trials and trial outcomes were extracted from ClinicalTrials.gov, classified, and analyzed. For pivotal trials, registrations were compared with matching publications and supplementary documentation. The adherence of outcomes in pivotal clinical trials to COE developed by the European Society of Cardiology (ESC) was checked.</div></div><div><h3>Results</h3><div>In 71 included trials, we found 170 individual clinical outcomes and divided them into 11 groups (10 clinical outcome groups and ESC COE). Heart failure with reduced ejection fraction (HFrEF) was analyzed in 33 (46%) trials, and heart failure with preserved ejection fraction (HFpEF) in 25% of trials. ESC COE outcomes were used in less than 30% of trials, and only in 9 as primary outcomes (13%). Trials included 59 different biomarker endpoints. Patient-reported outcomes were highly heterogeneous, utilizing various nonvalidated questionnaires. All five pivotal trials used primary outcomes from ESC COE. The adherence of pivotal trials to the ESC COE was moderately high, with insufficient data on dyspnea and heart failure events such as intensification of diuretic therapy. All pivotal trials had at least one change in study protocol at one point during the trial, in outcome measures, statistical model, enrollment, or trial duration.</div></div><div><h3>Conclusion</h3><div>Outcomes used in CHF trials of SGLT2 inhibitors were highly heterogeneous. Core outcome sets developed especially for CHF were underutilized. Standardization of outcomes is needed in the CHF field to enable between-trial comparisons and evidence syntheses.</div></div>","PeriodicalId":51079,"journal":{"name":"Journal of Clinical Epidemiology","volume":"180 ","pages":"Article 111685"},"PeriodicalIF":7.3000,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Epidemiology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0895435625000186","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives

This study aimed to analyze the outcomes, outcome domains, and prevalence of the use of clinical outcome endpoints (COE) in clinical trials on sodium-glucose cotransporter 2 (SGLT2) inhibitors for chronic heart failure (CHF) registered on ClinicalTrials.gov and compare them to COE for cardiovascular trials.

Study Design and Setting

We conducted a cross-sectional methodological study. Trials and trial outcomes were extracted from ClinicalTrials.gov, classified, and analyzed. For pivotal trials, registrations were compared with matching publications and supplementary documentation. The adherence of outcomes in pivotal clinical trials to COE developed by the European Society of Cardiology (ESC) was checked.

Results

In 71 included trials, we found 170 individual clinical outcomes and divided them into 11 groups (10 clinical outcome groups and ESC COE). Heart failure with reduced ejection fraction (HFrEF) was analyzed in 33 (46%) trials, and heart failure with preserved ejection fraction (HFpEF) in 25% of trials. ESC COE outcomes were used in less than 30% of trials, and only in 9 as primary outcomes (13%). Trials included 59 different biomarker endpoints. Patient-reported outcomes were highly heterogeneous, utilizing various nonvalidated questionnaires. All five pivotal trials used primary outcomes from ESC COE. The adherence of pivotal trials to the ESC COE was moderately high, with insufficient data on dyspnea and heart failure events such as intensification of diuretic therapy. All pivotal trials had at least one change in study protocol at one point during the trial, in outcome measures, statistical model, enrollment, or trial duration.

Conclusion

Outcomes used in CHF trials of SGLT2 inhibitors were highly heterogeneous. Core outcome sets developed especially for CHF were underutilized. Standardization of outcomes is needed in the CHF field to enable between-trial comparisons and evidence syntheses.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Clinical Epidemiology 医学-公共卫生、环境卫生与职业卫生

CiteScore

12.00

自引率

6.90%

发文量

320

审稿时长

44 days

期刊介绍： The Journal of Clinical Epidemiology strives to enhance the quality of clinical and patient-oriented healthcare research by advancing and applying innovative methods in conducting, presenting, synthesizing, disseminating, and translating research results into optimal clinical practice. Special emphasis is placed on training new generations of scientists and clinical practice leaders.